| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
Patients with chronic kidney disease (CKD) are characterized by wasting or catabolic state in parallel with the disease progression, which may be associated with an increased risk of cardiovascular events and mortality. “Uremic toxin” accumulated in advanced CKD may be responsible for the disturbance of insulin action in this pathophysiology. Number of substances are known as a uremic toxin, most of which are produced by the gut microbiota. We showed that uremic toxins are involved in the disturbance of insulin action and catabolic state of CKD, and thus the development of an efficient removal technology is required.
|
